Leukocyte cell population data as potential markers of COVID-19 disease characterization
leukocyte parameters and COVID-19
Abstract
Introduction
The usefulness of leukocyte cell population data (CPD) is currently being investigated. In COVID-19 pandemic several reports showed the clinical importance of blood parameters. Our study aimed to assess CPDs in Sars Cov-2 patients as new disease markers. Methods From February to April 2020 (1st wave) 540 and from September to December 2020 (2nd wave) 2821 patients respectively were enrolled. SARS CoV-2 infection diagnosis was carried out by Multiplex rRT-PCR from nasopharyngeal swabs. CPDs were detected by XN 2000 hematology analyzer (Sysmex Corporation). A comparison between two disease waves was performed. Additionally, C-reactive protein (CRP) and lactate dehydrogenase (LDH) were assayed.
Results
CPDs were classified into: cell complextity, DNA/RNA content and abnormal sized cells. We detected parameters increased from the reference population for all cell types for both 1st and 2nd wave (p≤ 0.03). However, in the 2nd vs 1st wave 5 CPDs vs 9 CPDs were found. In addition we observed higher CPD values of the 1st compared to 2nd wave: (NE-SFL) (p=00004), (LY-Y) (p≤0.0001), (LY-Z) (p≤0.0001), (MO-X) (p≤0.0001), (MO-Y) (p≤0.0001). These findings were confirmed by the higher concentrations of CRP and LDH in the 1st vs 2nd wave: 17.3 mg/L (8.5-59.3) vs 6.3 mg/L (2.3-17.6) (p=0.0003) and 241.5 UI/L (201-345) vs 195 UI/L (174-228) (p=0.0005)(median, interquartile range) respectively.
Conclusion
Leukocyte CPDs showed increased cell activation in patients of 1st wave confirmed by clinical and biochemical data, correlated with worse clinical conditions. Our results highlighted the CPDs as disease characterization markers or useful for a risk model.
References
1. Rossi C, Berta P, Curello S, et al. The impact of COVID-19 pandemic on AMI and stroke mortality in Lombardy: Evidence from the epicenter of the pandemic. PLOS ONE | https://doi.org/10.1371/journal.pone.0257910 October 1, 2021
2. Scortichini M, Schneider do Santos R, De’ Donato F, et al. Excess mortality during the COVID-19 outbreak in Italy: a two-stage interrupted time-series analysis. International Journal of Epidemiology, 2020, Vol. 49, No. 6
3. De Filippo O, D’Ascenzo F, Angelini F, et al. Reduced rate of hospital admission for ACS during Covid-19 outbreak in Northern Italy. N Engl J Med. 2020;383(1):88-89.
4. Rind I A, Cannata A, McDonaugh B et. al., Patients hospitalised with heart failure across different waves of the COVID-19 pandemic show consistent clinical characteristics and outcomes. International Journal of Cardiology 350 (2022) 125–129.
5. Lombardi A, Trombetta E, Cattaneo A, et al. Early phases of COVID-19 are characterized by a reduction in lymphocyte populations and the presence of atypical monocytes. Front Immunol. 2020;11:560330. 10.3389/fimmu.2020.560330
6. Huang W, Berube J, Mcnamara M, et. al. Lymphocyte Subset Counts in COVID-19 Patients: A Meta-Analysis. Cytometry Part A _ 2020
7. Wu D, Wu X, Huang J, et. al. Lymphocyte subset alterations with disease severity, imaging manifestation, and delayed hospitalization in COVID-19 patients. BMC Infectious Diseases (2021) 21:631 https://doi.org/10.1186/s12879-021-06354-7
8. Rydyznski Moderbacher C, Ramirez SI, Dan JM, et. al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell. 2020 Nov 12; 183(4): 996–1012.e19. doi: 10.1016/j.cell.2020.09.038
9. Ognibene A, Lorubbio M, Magliocca P, et. al. Elevated monocyte distribution width in COVID-19 patients: The contribution of the novel sepsis indicator. Clinica Chimica Acta 509 (2020) 22–24
10. Lapic I, Brencic T, Rogic D, et. al. Cell population data: Could a routine hematology analyzer aid in the differential diagnosis of COVID-19? Int J Lab Hematol. 2020;00:1–4.
11. Vasse M, Ballester MC, Ayaca D, et. al. Interest of the cellular population data analysis as an aid in the early diagnosis of SARS-CoV-2 infection. Int J Lab Hematol. 2021;43:116–122
12. Naoum FA, Laridondo Zucarelli Ruis A, De Oliveira Martin FH, et. al. Diagnostic and prognostic utility of WBC counts and cell population data in patients with COVID-19. Int J Lab Hematol. 2021;43(Suppl. 1):124–128
13. Cheng Y, Zhao H, Song P, Zhang Z, Chen J, Zhou YH. Dynamic changes of lymphocyte counts in adult patients with severe pandemic H1N1 influenza A. J Infect Public Health. 2019;12(6):878-883
14. Buoro S, Seghezzi M, Vavassori , et. al. Clinical significance of cell population data (CPD) on Sysmex XN-9000 in septic patients with or without liver impairment. Ann Transl Med 2016;4(21):418
15. Urrechaga E, Boveda O, Aguirre U. Role of leucocytes cell population data in the early detection of sepsis. J Clin Pathol. 2018 Mar;71(3):259-266
16. Lapic I, Brencic T, Rogic D, et. al. Cell population data: Could a routine hematology analyzer aid in the differential diagnosis of COVID-19? Int J Lab Hematol. 2020;00:1–4.
17. Vasse M, Ballester MC, Ayaka D e. al. Interest of the cellular population data analysis as an aid in the early diagnosis of SARS-CoV-2 infection. Int J Lab Hematol. 2021;43:116–122
18. Diagnostic and prognostic utility of WBC counts and cell population data in patients with COVID-19. Int J Lab Hematol. 2021;43(Suppl. 1):124–128
19. Zini G, Bellesi S, Ramundo F, d’Onofrio G. Morphological anomalies of circulating blood cells in COVID-19. Am J Hematol. 2020 Jul;95(7):870-872
20. MacFadyen JD, Stevens H, Peter K. The emerging threat of (Micro)
thrombosis in COVID-19 and its thearapeutic implications. Circ Res. 2020;127:571-587
21. Introcaso G, Bonomi A, Salvini L, et. al. High immature platelet fraction with reduced platelet count on hospital admission. Can it be useful for COVID-19 diagnosis? Int J Lab Hematol. 2021;00:1–6
22. Foieni F, Sala G, Mognarelli JG, et. al. Derivation and validation of the clinical prediction model for COVID‑19. Internal and Emergency Medicine (2020) 15:1409–1414
23. Campagner A, Carobene A, Cabitza F. External validation of Machine Learning models for COVID‑19 detection based on Complete Blood Count. Health Inf Sci Syst (2021) 9:37
24. Berry DA, Ip A, Lewis BE, et. al. Development and validation of a prognostic 40-day mortality risk model among hospitalized patients with COVID-19. PLOS ONE | https://doi.org/10.1371/journal.pone.0255228 July 30, 2021
Copyright (c) 2023 Giovanni Introcaso, Arianna Galotta, Alice Bonomi, Laura Salvini, Emilio Assanelli, Elena Maria Faioni, Maria Luisa Biondi
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.